Why Won't My Employer Cover GLP-1? 2026 Coverage Gap

More U.S. employers are dropping GLP-1 weight-loss coverage as costs climb, and patients who lose it can face more than $1,000 per month out of pocket. ABC News reported on August 29, 2026 that Cigna stopped covering GLP-1s for weight loss in its own employee health plan on July 1, 2026, and PepsiCo cut weight-loss coverage for employees while continuing to cover the drugs for diabetes (ABC News, Aug 29, 2026). Here is what is happening, why employers keep saying no, and what GLP-1 costs in 2026 when insurance does not pay.

Why Won’t My Employer Cover GLP-1?

The short answer is that it is largely a business decision, not a medical one. ABC News quoted PepsiCo’s letter to employees saying that “prescription weight loss medications have become one of the fastest-growing costs in the PepsiCo Plans,” and that removing the benefit keeps the healthcare program “sustainable and affordable” for everyone (ABC News, Aug 29, 2026).

The cost pressure is measurable. Among employers that cover GLP-1s, the drugs represented an average of 11.4% of total annual claims in 2025, up from 10.5% in 2024 (Becker’s Payer Issues / IFEBP, Jul 7, 2026). KFF research, cited by ABC News, found that “many employers find use of GLP-1s is higher than expected and covering them significantly increased prescription drug costs, leading to considerations of scaling back coverage” (ABC News, Aug 29, 2026). Employers also cite a long payoff horizon: Northwestern’s Dr. Xiaoning Huang told ABC News the benefits may not show for “10, 20 years from now” (ABC News, Aug 29, 2026). The evidence base keeps moving while employers weigh that payoff horizon: a UK records analysis at the ERS Congress associated semaglutide with fewer asthma attacks and COPD flare-ups, observational, not peer-reviewed and not an approved use — see our coverage of semaglutide and the ERS 2026 asthma/COPD signal.

Coverage is also not legally required. Weight loss “isn’t required by law to be covered, so insurance companies can opt out” (Noom, updated Aug 20, 2026).

Does My Insurance Cover GLP-1?

Not necessarily. In a June 2026 survey of more than 31,000 employer organizations, only 36% covered GLP-1s for both diabetes and weight loss, 60% covered them for diabetes only, and 3% did not cover them at all (Becker’s Payer Issues / IFEBP, Jul 7, 2026). KFF’s Employer Health Benefits Survey shows the same stall: employers offering obesity-drug coverage edged from 18% in 2024 to 19% in 2025, while the share not offering it rose from 52% to 57% (NPR, Apr 22, 2026).

Coverage is shrinking, not just patchy. GoodRx and MMIT data reported by NPR found that from 2025 to 2026, 12 million people lost coverage for Zepbound and 12 million lost it for Wegovy (NPR, Apr 22, 2026). Even among covered patients, 88% face some kind of restriction, and 95% of employer cost-control programs require prior authorization (NPR, Apr 22, 2026, Becker’s Payer Issues / IFEBP, Jul 7, 2026).

GLP-1 Cost 2026: What You Pay Without Coverage

If your plan says no, the bill is steep — and it varies by channel:

• Out of pocket with no coverage: more than $1,000/month for some patients; depending on plan, drug, and cash-pay programs, costs range from $25 to over $1,000/month (ABC News, Aug 29, 2026).
• Brand-name list prices: $998–$1,349/month for semaglutide (Wegovy, Ozempic); Zepbound lists around $499–$1,086 per fill (SingleCare, Noom, updated Aug 20, 2026, ABC News, Aug 29, 2026).
• Manufacturer cash-pay programs: NovoCare self-pay runs $149–$399/month, and the oral Wegovy pill starts at $149/month (Noom, updated Aug 20, 2026).
• Compounded semaglutide via telehealth: roughly $99–$397/month depending on provider and formulation (PeptidesBeat GLP-1 pricing hub).
• With insurance plus a savings card: as low as $25/month (ABC News, Aug 29, 2026, Noom, updated Aug 20, 2026).
• On Medicare: eligible Part D members get brand-name GLP-1s for $50/month through the GLP-1 Bridge, which started July 1, 2026 and runs through December 31, 2027 (ABC News, Aug 29, 2026).

How Much Is Semaglutide Without Insurance?

Between $129 and $1,865 per month, depending on formulation and channel. SingleCare puts the full no-insurance range at $129/month for compounded products up to $1,865/month for FDA-approved products at retail (SingleCare). Most people do not pay list price: brand-name semaglutide lists at $998–$1,349/month, but NovoCare self-pay runs $149–$399/month and compounded telehealth plans run about $99–$397/month (Noom, updated Aug 20, 2026, PeptidesBeat GLP-1 pricing hub). Our GLP-1 cost comparison hub breaks down every channel side by side. For the newest Health Canada authorization of a generic semaglutide — Sandoz’s, in September 2026 — and what it does and does not change about price, see our Canadian generic semaglutide explainer.

What to Do If Your Employer Stops Covering GLP-1

• Ask about manufacturer savings cards. Covered patients can often pay $25 or less per month (Noom, updated Aug 20, 2026).
• Compare cash-pay and telehealth options. Compare GLP-1 telehealth options side by side — including DirectMeds’ $249/month all-inclusive program — and see the oral GLP-1 comparison for lower-cost brand options. Fewer than a third of GLP-1 telehealth sites required a real-time consultation — our report sets out the numbers: GLP-1 Telehealth: Fewer Than a Third Consult a Doctor. Our method for reading any of these tables — ours included — is set out in How to Tell If a GLP-1 Price Comparison Is Trustworthy.
• Check the compounding landscape. Budget compounded supply is tightening after the Fifth Circuit’s compounded GLP-1 ruling — see why compounded GLP-1 supply is ending.
• If you are on Medicare, confirm whether you qualify for the $50/month GLP-1 Bridge (ABC News, Aug 29, 2026).
• Talk to your clinician before stopping. Northwestern’s Dr. Sadiya Khan told ABC News that for patients already benefiting, “stopping it because it’s no longer covered is a really big deal” (ABC News, Aug 29, 2026). Before you make that call, see what the evidence says about why people stop semaglutide — and what tends to follow.

FAQ

Why won’t my employer cover GLP-1?

GLP-1s have become one of the fastest-growing costs in employer health plans, and covering them significantly increased prescription drug costs — which has led some employers, including Cigna and PepsiCo, to scale back or drop weight-loss coverage. Only about a third of employers (36%) cover GLP-1s for both diabetes and weight loss (ABC News, Aug 29, 2026, Becker’s Payer Issues / IFEBP, Jul 7, 2026).

Does my insurance cover GLP-1?

Not necessarily. Weight-loss coverage is not required by law, 60% of employers cover GLP-1s only for diabetes, and even covered patients often face prior authorization or BMI requirements (Noom, updated Aug 20, 2026, Becker’s Payer Issues / IFEBP, Jul 7, 2026).

How much does GLP-1 cost in 2026?

From about $69/month on the cheapest compounded telehealth plans to more than $1,349/month for brand-name Wegovy at list; with insurance and a savings card, many people pay $25 or less, and eligible Medicare Part D members pay $50/month through the GLP-1 Bridge (PeptidesBeat GLP-1 pricing hub, ABC News, Aug 29, 2026).

How much is semaglutide without insurance?

$129 to $1,865/month depending on formulation and channel; brand list price is $998–$1,349/month, but NovoCare self-pay runs $149–$399/month and compounded telehealth plans run about $99–$397/month (SingleCare, Noom, updated Aug 20, 2026, PeptidesBeat GLP-1 pricing hub).

What happens if my employer stops covering GLP-1s?

You may face more than $1,000/month out of pocket. Some people switch to cash-pay, compounded, or telehealth options, and clinicians warn that stopping treatment after benefit can carry cardiovascular risk — talk to your doctor first (ABC News, Aug 29, 2026).

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.